Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining bortezomib with gemcitabine and
carboplatin in treating patients who have advanced or recurrent non-small cell lung cancer
that has not been previously treated with chemotherapy. Drugs used in chemotherapy, such as
gemcitabine and carboplatin, work in different ways to stop tumor cells from dividing so they
stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes
necessary for their growth. Bortezomib may also help gemcitabine and carboplatin kill more
tumor cells by making the cells more sensitive to the drugs